Prostate Cancer Program Offers New Technology | News | Loyola Medicine
Wednesday, May 24, 2017

Loyola's Prostate Cancer Program Offers Patients Leading-Edge Technology, Experience and Expertise

UroNav prostate cancer screening test

MAYWOOD, IL –  When Mike Marks learned he had an elevated level on a PSA prostate cancer screening test, he considered several other centers before choosing Loyola Medicine.

Mr. Marks was impressed with Loyola’s use of an advanced MRI technology to help detect prostate cancer. He met with urologic oncologist Gopal Gupta, MD, and was impressed with Dr. Gupta’s experience and expertise in using the technology.

Loyola was the first center in Illinois to offer the new biopsy technique for patients who have high scores on PSA blood tests. The technique, called UroNav, fuses information from a prostate MRI to ultrasound images taken during the biopsy. The technique results in higher cancer detection, more confidence that negative findings are accurate, fewer biopsies and more accurate biopsies. Dr. Gupta, who had advanced training in the technique at the National Cancer Institute, leads the program at Loyola.

Mr. Marks’ MRI-ultrasound fusion biopsy pinpointed cancer in the right and left sides and core areas of his prostate. After discussing various treatment options with Dr. Gupta, Mr. Marks decided to undergo robotic surgery to remove his prostate and lymph nodes.

The robotic system includes robotic arms that are equipped with small video cameras and miniaturized surgical tools. The system allows the surgeon to visualize the surgical field in 3D for the best outcomes. Sitting at a console, the surgeon views a highly magnified image of the surgical site. Every maneuver of the robot is directed by the surgeon in real time. The robot makes no decisions on its own.

Mr. Marks said he and his family were reassured when they learned that Dr. Gupta has performed more than 400 robotic surgeries and is a national expert in the field.

The minimally invasive robotic surgery results in less blood loss, shorter hospital stays and quicker recoveries. Mr. Marks went home the day after his surgery and experienced minimal pain.

At the first post-operative visit, Dr. Gupta reviewed the pathology results and confirmed the cancer was fully removed and Mr. Marks’ recovery was excellent.

“My experience at Loyola was outstanding,” Mr. Marks said.

About Loyola Medicine

Loyola Medicine is a member of Trinity Health. Based in the western suburbs of Chicago, LUHS is a quaternary care system that includes Loyola University Medical Center (LUMC), located on a 61-acre campus in Maywood, Gottlieb Memorial Hospital (GMH), on a 36-acre campus in Melrose Park, and convenient locations offering primary and specialty care services throughout Cook, Will and DuPage counties. At the heart of LUMC is a 547-licensed-bed hospital that houses the Center for Heart & Vascular Medicine, the Cardinal Bernardin Cancer Center, a Level 1 trauma center, a burn center, a children's hospital, Loyola Outpatient Center, and Loyola Oral Health Center. The campus also is home to Loyola University Chicago Stritch School of Medicine, Loyola University Chicago Marcella Niehoff School of Nursing and the Loyola Center for Fitness. The GMH campus includes a 254-licensed-bed community hospital, a Professional Office Building with 150 private practice clinics, an adult day care program, the Gottlieb Center for Fitness, the Loyola Center for Metabolic Surgery and Bariatric Care and the Loyola Cancer Care & Research at the Marjorie G. Weinberg Cancer Center at Melrose Park.

Trinity Health is one of the largest multi-institutional Catholic health care delivery systems in the nation. It serves people and communities in 22 states from coast to coast with 93 hospitals, and 120 continuing care locations — including home care, hospice, PACE and senior living facilities — that provide nearly 2.5 million visits annually.